Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05284877
Other study ID # HPV Skin Cancer OTR
Secondary ID Journal-nr.: H-2
Status Recruiting
Phase
First received
Last updated
Start date March 10, 2022
Est. completion date April 2027

Study information

Verified date March 2023
Source Bispebjerg Hospital
Contact Lene Rask
Phone +45 23359940
Email lene.rask.01@regionh.dk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression. The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs. This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 600 male OTRs and 600 female controls will be included from Danish dermatology departments. The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.


Description:

AIMS The specific research objectives of this study are: 1. To investigate the overall and type-specific prevalence, incidence and persistence of cervical HPV infection in OTRs compared to immunocompetent controls. 2. To investigate the overall and type-specific prevalence of oral HPV infection in female OTRs compared to immunocompetent controls. 3. To determine the role of lifestyle and clinical factors for the occurrence of cervical and oral HPV infection in female OTRs. 4. To investigate the prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared with immunocompetent controls. 5. To determine the role of lifestyle, clinical and organ transplantation-related factors for the prevalence and incidence of skin dysplasia in OTRs. 6. To investigate associations between skin dysplasia and prevalence of cervical HPV infection and VZV infection in OTRs. METHODS The study will be designed as a clinical prospective cohort study. A total of 600 female OTRs, 600 male OTRs and 600 female immunocompetent controls will be included from the Departments of Dermatology at Bispebjerg, Gentofte and Roskilde Hospitals, Denmark. The following data will be collected from OTRs: - At baseline: Questionnaire, dermatologic skin assessment, assessment of skin photodamage (only OTRs recruited from Bispebjerg Hospital), medical record information, cervico-vaginal HPV self-sample test (women only), oral sample for HPV test (women only), blood sample for future research, blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital). - After 6 months: New blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital). - After 12 months: New cervico-vaginal HPV self-sample test (women only). The following data will be collected from female immunocompetent controls: - At baseline: Questionnaire, cervico-vaginal HPV self-sample test, oral sample for HPV test. - After 12 months: New cervico-vaginal HPV self-sample test. A REDCap database will be established for study data. The RedCap database is encrypted and accessed electronically with personal user-ID and password. The study population will be linked with nationwide Danish registries and clinical databases. From these registers information on cases of precancerous lesions and cancer; other HPV-related conditions; participation in HPV vaccination and cervical cancer screening; co-morbidities, pregnancies, births and medicine use; socio-demographic characteristics; and emigration and death of women in the study population will be obtained. Registry linkage will be performed for up to 15 years after end of study.


Recruitment information / eligibility

Status Recruiting
Enrollment 1800
Est. completion date April 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for OTRs: - Patients aged =18 years - Solid organ transplantation recipients, i.e. kidney-, liver-, lung-, and heart transplant recipients - Stable immunosuppressive treatment for =3 months - No signs of acute graft rejection - Patients who reside in Denmark - Informed written consent obtained Exclusion Criteria for OTRs: - Patients with concomitant bone marrow transplantation - Full hysterectomy Inclusion Criteria for Control group: - Able patients aged =18 years - No known immunosuppressive therapy or -condition - Patients who reside in Denmark - Informed written consent obtained Exclusion Criteria for Control group: - Full hysterectomy

Study Design


Intervention

Other:
No intervention
The study is an observational study without intervention.

Locations

Country Name City State
Denmark Department of Dermatology, Bispebjerg Hospital Copenhagen NV Region Hovedstaden
Denmark Department of Dermatology and Allergy, Herlev og Gentofte Hospital Hellerup Region Hovedstaden
Denmark Department of Dermatology, Zealand University Hospital Roskilde Region Sjælland

Sponsors (6)

Lead Sponsor Collaborator
Merete Haedersdal Danish Cancer Society, Herlev and Gentofte Hospital, Rigshospitalet, Denmark, Vejle Hospital, Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls. Number of women with cervical HPV infection measured by PCR test. Evaluated at baseline and month 12
Secondary Difference in prevalence of oral HPV infection in female OTRs compared to immunocompetent controls. Number of women with oral HPV infection measured by PCR test. Evaluated at baseline
Secondary Correlations between lifestyle factors, clinical factors and occurrence of cervical HPV infection in female OTRs. Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with cervical HPV infection measured by PCR test. Evaluated at baseline
Secondary Correlations between lifestyle factors, clinical factors and occurrence of oral HPV infection in female OTRs. Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with oral HPV infection measured by PCR test. Evaluated at baseline
Secondary Difference in prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared to immunocompetent controls. Number of women with HPV-related dysplasia and HPV-related cancer from registries using registry linkage. Evaluated at baseline and during up to 15 years after baseline.
Secondary Correlations between lifestyle factors, clinical factors and prevalence of skin dysplasia and cancer in OTRs. Lifestyle factors determined by a questionnaire. Clinical factors from medical records. Skin dysplasia and skin cancer assessed by clinical evaluation and by non-invasive imaging. Evaluated at baseline
Secondary Correlation between Vitamin D and prevalence of skin dysplasia and cancer in OTRs. Vitamin D from blood sample analysis. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging. Evaluated at baseline
Secondary Correlations between skin pigmentation, facial solar lentigines and prevalence of skin dysplasia and cancer in OTRs. Skin pigmentation measured with skin reflectance. Facial solar lentigines measured by photographs. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging. Evaluated at baseline
Secondary Correlation between prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs. Number of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging. Evaluated at baseline
Secondary Correlations between history of herpes zoster, prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs. Number of women with history of herpes zoster determined by questionnaire. Number of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging. Evaluated at baseline
Secondary Difference in prevalence and incidence of skin cancer in female OTRs compared to immunocompetent controls. Number of women with skin cancer from registries using registry linkage Evaluated at baseline and during up to 15 years after baseline.
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A